ArticleFrontiers in oncology2026
Optimizing outcomes with less than more: multi-institutional experience of fast-forward fractionation and the impact of dosimetric parameters on toxicity in breast cancer patients.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The FAST-Forward trial demonstrated the non-inferiority of 26 Gy in five fractions compared to 40 Gy in 15 fractions over five years. This study aimed to report observed breast toxicities and examine the impact of dosimetric parameters in ultra-hypofractionated radiotherapy (RT) across a diverse patient population in Saudi Arabia. Methods: This multi-institutional retrospective study evaluated 100 breast cancer patients treated with whole-breast adjuvant radiotherapy (26 Gy in 5 fractions) between June 2020 and June 2023, with adjuvant RT at two different institutions in Saudi Arabia. Breast toxicity data were retrospectively collected from medical chart review and verbal reports from patients lost to follow-up. Correlations between dosimetric factors, body mass index (BMI), and acute and late toxicity symptoms were statistically assessed. Results: A total of 85 patients were included in the analysis after excluding those with incomplete toxicity data with a median follow-up of 19 months. Breast skin dermatitis was the most common side effect (82.35%, n=70) with 5% of patients experiencing Grade III, followed by hyperpigmentation (72.9%, n=62), breast discomfort (30.3%, n=26) and breast hardness (17.6%, n=15). Breast pain rated ≥5 out of 10 on the pain scale was reported in 15% of cases. Breast pain had a significant correlation with larger breast volume and higher V107% values (p=0.013, and p=0.012 respectively). Furthermore, breast skin dermatitis was significantly correlated with breast CTV, BMI, and breast separation (p=0.0001, 0.015, and 0.001 respectively). Conclusions: Ultra-hypofractionated RT with a 26 Gy in five fractions schedule was well tolerated in our patient cohort. A larger breast volume, higher BMI, and increased V105% and V107% were associated with greater toxicity. Optimizing modifiable dosimetric factors may reduce adverse effects. Consequently, these findings offer valuable insights into treatment refinement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.